References

Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN

10.1136/gutjnl-2022-327736 · 2023 · External reference

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2021 · External reference

Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

10.1016/j.annonc.2022.10.003 · 2023 · External reference

Current and emerging concepts for systemic treatment of metastatic colorectal cancer

10.1136/gutjnl-2025-335412 · 2025 · External reference

Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology

2024 · External reference

Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data

10.1634/theoncologist.2014-0032 · 2014 · External reference

Late-line options for patients with metastatic colorectal cancer: a review and evidence-based algorithm

10.1038/s41571-024-00965-0 · 2025 · External reference

Tas-102 for refractory metastatic colorectal cancer: a multicenter retrospective cohort study

10.3390/cancers15133465 · 2023 · External reference

Biweekly dosing of trifluridine-tipiracil reduces rates of myelosuppression while maintaining efficacy in patients with metastatic colorectal cancer

10.1093/oncolo/oyaf099 · 2025 · External reference

Randomized trial of TAS-102 for refractory metastatic colorectal cancer

10.1056/nejmoa1414325 · 2015 · External reference

Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis

10.1136/esmoopen-2020-000752 · 2020 · External reference

Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102

2017 · External reference

Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial

10.1001/jama.2017.7105 · 2017 · External reference

Impact of bevacizumab on clinical outcomes and its comparison with standard chemotherapy in metastatic colorectal cancer patients: a systematic review and meta-analysis

10.1080/20523211.2024.2354300 · 2024 · External reference

Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis

10.1186/s12876-024-03134-w · 2024 · External reference

Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, together with bevacizumab, cetuximab, or panitumumab on human colorectal cancer xenografts

2015 · External reference

TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): an investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study

10.1016/s1470-2045(17)30425-4 · 2017 · External reference

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

10.1016/s1470-2045(19)30827-7 · 2020 · External reference

Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer

10.1056/nejmoa2214963 · 2023 · External reference

Harnessing the potential of real-world evidence in the treatment of colorectal cancer: where do we stand?

10.1007/s11864-024-01186-4 · 2024 · External reference

TAS-102 (trifluridine/tipiracil) plus bevacizumab versus TAS-102 alone as salvage treatment options for metastatic colorectal cancer in routine clinical practice

10.3389/fonc.2024.1450732 · 2024 · External reference

Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan

10.1016/j.esmoop.2023.101614 · 2023 · External reference

Effects and risk factors of TAS-102 in real-world patients with metastatic colorectal cancer, EROTAS-R study

10.1007/s10147-023-02389-9 · 2023 · External reference

Real-world clinical outcomes of trifluridine-tipiracil monotherapy (FTD-TPI) and FTD-TPI + bevacizumab combination therapy (FTD-TPI+bev) in 639 black patients (pts) with metastatic colorectal cancer (mCRC)

10.1200/jco.2025.43.4_suppl.81 · 2025 · External reference

Real-world comparison of trifluridine–tipiracil with or without bevacizumab in patients with refractory metastatic colorectal cancer

10.3390/biomedicines13040976 · 2025 · External reference

Impact of KRASG12 mutations on survival with trifluridine/tipiracil plus bevacizumab in patients with refractory metastatic colorectal cancer: post hoc analysis of the phase III SUNLIGHT trial

10.1016/j.esmoop.2024.102945 · 2024 · External reference

Real-world data of patients with BRAF V600E-mutated metastatic colorectal cancer treated with trifluridine/tipiracil

10.3390/cancers16244140 · 2024 · External reference

The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: a Portuguese exploratory analysis

2022 · External reference

P-301 Benefit of adding bevacizumab to trifluridine/tipiracil in different prognostic groups of metastatic colorectal cancer: a Portuguese exploratory analysis

10.1016/j.annonc.2023.04.357 · 2023 · External reference

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

10.1016/j.annonc.2019.10.005 · 2020 · External reference

Effect of neutropenia on survival outcomes of patients with metastatic colorectal cancer receiving trifluridine/tipiracil plus bevacizumab

10.3892/ol.2021.13044 · 2021 · External reference

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias

10.1186/s12885-023-11618-3 · 2023 · External reference

The frequency of specific KRAS mutations, and their impact on treatment choice and survival, in patients with metastatic colorectal cancer

10.1093/oncolo/oyad117 · 2023 · External reference

The relationship of KRAS expression with KRAS status, prognosis, and tumor-infiltrated T lymphocytes in colorectal cancer

10.1177/17562848241249387 · 2024 · External reference

P-240 Frequency and management of trifluridine/tipiracil (FTD/TPI) + bevacizumab (BEV)-associated neutropenia in patients with refractory metastatic colorectal cancer (mCRC) in real-world practice

10.1016/j.annonc.2023.04.296 · 2023 · External reference

Use of granulocyte colony-stimulating factor in patients with chemotherapy-induced neutropaenia

2023 · External reference

Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

10.3389/fonc.2024.1506075 · 2025 · External reference